The storm of NGS in NSCLC diagnostic-therapeutic pathway: How to sun the real clinical practice

Maglio, Giovanna De; Pasello, Giulia; Dono, Mariella; Fiorentino, Michelangelo; Follador, A.; Sciortino, Marianna; Malapelle, Umberto; Tiseo, Marcello

doi:10.1016/j.critrevonc.2021.103561

Cited by 27 publications

(30 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With the development of gene sequencing technology, NGS has become the most frequently used method for detecting and analyzing the tumor genotypes of NSCLC in clinical practice ( 35 ). Although the consistency of NGS and other methods for TP53 sequencing requires further validation, the predictive value of NGS-detected TP53 mutations was consistent with TP53 mutations detected using other methods according to the current subgroup analysis.…”

Section: Discussionmentioning

confidence: 99%

Concurrent TP53 mutations predict a poor prognosis of EGFR‑mutant NSCLCs treated with TKIs: An updated systematic review and meta‑analysis

Lan

Zhao

et al. 2022

Oncol Lett

View full text Add to dashboard Cite

The prognostic value of tumor protein P53 (TP53) mutation for tyrosine kinase inhibitor (TKI) treatment in EGFR-mutant non-small-cell lung cancer (NSCLC) remains controversial. Therefore, the present meta-analysis was performed to investigate the potential association between the prognosis of TKI treatment for patients with advanced EGFR mutation-positive NSCLC and the presence or absence of concurrent TP53 mutations. In the present study, 24 eligible studies from the PubMed, Embase and Cochrane databases were identified by screening prior to inclusion. Data were extracted by two independent investigators and analyzed using STATA 14.0 software. Pooled odds ratios (ORs) with 95% confidence interval (CIs) were used to determine the association between objective response rates (ORRs) and TP53 mutations. In addition, differences in the incidence of TP53 mutations between patients with exon 21 L858R mutations and exon 19 deletions of EGFR were evaluated using this method. Pooled hazard ratios (HRs) with 95% CIs were used to calculate the prognostic value of TP53 mutations for progression-free survival (PFS) and overall survival (OS). No significant difference in the incidence of TP53 mutations was detected between the patients with exon 21 L858R mutation and those with exon 19 deletion (OR=0.91; 95% CI=0.65-1.27; P=0.568). However, the pooled results revealed that TP53 mutations were significantly associated with shorter PFS (HR=1.51; 95% CI=1.33-1.71; P<0.001) and OS (HR=1.64; 95% CI=1.33-2.02; P<0.001). By contrast, TP mutations were not associated with the ORR of EGFR-TKI treatment (OR=0.91; 95% CI=0.69-1.21; P=0.529). In conclusion, a worse prognosis for TKI treatment was observed in patients with EGFR-mutant NSCLCs and concurrent TP53 mutations, suggesting that TP53 mutations is associated with primary resistance to EGFR-TKIs.

show abstract

Section: Discussionmentioning

confidence: 99%

Concurrent TP53 mutations predict a poor prognosis of EGFR‑mutant NSCLCs treated with TKIs: An updated systematic review and meta‑analysis

Lan

Zhao

et al. 2022

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…In nonsquamous NSCLC, tumor multigene NGS is recommended for the identification of genomic alterations with a predictive value that has been established in clinical trials [ 31 ]. Among these alterations, EGFR in-frame activating mutations in exon 19 and point-activating mutations in exon 21 (L858R) predict the efficacy of EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib and gefitinib; mutations in exon 20, on the other hand, are associated with the acquisition of drug resistance [ 32 , 33 ].…”

Section: Ngs In Clinical Practicementioning

confidence: 99%

FFPE-Based NGS Approaches into Clinical Practice: The Limits of Glory from a Pathologist Viewpoint

Cappello

Angerilli

Munari

et al. 2022

JPM

Self Cite

View full text Add to dashboard Cite

The introduction of next-generation sequencing (NGS) in the molecular diagnostic armamentarium is deeply changing pathology practice and laboratory frameworks. NGS allows for the comprehensive molecular characterization of neoplasms, in order to provide the best treatment to oncologic patients. On the other hand, NGS raises technical issues and poses several challenges in terms of education, infrastructures and costs. The aim of this review is to give an overview of the main NGS sequencing platforms that can be used in current molecular diagnostics and gain insights into the clinical applications of NGS in precision oncology. Hence, we also focus on the preanalytical, analytical and interpretative issues raised by the incorporation of NGS in routine pathology diagnostics.

show abstract

“…Owing to the extensive requirements of biomarker testing for NS-NSCLC, next-generation sequencing (NGS) has become the optimal approach for parallel assessment of gene alterations. 4 , 6 , 7 Nevertheless, NGS can be difficult to master and can lead to a long turnaround time (TAT) to receive the results, which is often not compatible with international guidelines. 8 , 9 Therefore, many laboratories still rely on single gene and sequential approaches (such as IHC, fluorescence in situ hybridization [FISH], and targeted sequencing) to obtain rapid results in daily practice.…”

Section: Introductionmentioning

confidence: 99%

Ultrafast Gene Fusion Assessment for Nonsquamous NSCLC

Hofman¹,

Heeke²,

Bontoux³

et al. 2023

JTO Clinical and Research Reports

View full text Add to dashboard Cite

The storm of NGS in NSCLC diagnostic-therapeutic pathway: How to sun the real clinical practice

Cited by 27 publications

References 89 publications

Concurrent TP53 mutations predict a poor prognosis of EGFR‑mutant NSCLCs treated with TKIs: An updated systematic review and meta‑analysis

Concurrent TP53 mutations predict a poor prognosis of EGFR‑mutant NSCLCs treated with TKIs: An updated systematic review and meta‑analysis

FFPE-Based NGS Approaches into Clinical Practice: The Limits of Glory from a Pathologist Viewpoint

Ultrafast Gene Fusion Assessment for Nonsquamous NSCLC

Contact Info

Product

Resources

About